Government set up quality control regulations and validations of herbal medicines

Image
Capital Market
Last Updated : Feb 06 2018 | 6:31 PM IST
Central Government has published Ayurvedic pharmacopoeia containing quality standards of 645 single Ayurvedic drugs and 202 compound formulations; Unani Pharmacopoeia containing quality standards of 298 single drugs and 150 compound formulations and Siddha pharmacopoeia containing quality standards of 139 single drugs. Standardised 985 Ayurvedic Formulations, 1229 Unani Formulations and 399 Siddha Formulations are published in respective Formularies. Development of standards of ASU medicines is a ongoing process taken up by Pharmacopoieal Commission of Indian Medicine & Homeopathy and Pharmacopoeia Committees. Central and State Drug Laboratories for testing of ASU medicines are in place and as of now 55 laboratories are approved under the provisions of Drugs & Cosmetics Rules, 1945. It is mandatory for the manufacturers to adhere to the prescribed requirements for licensing of manufacturing units & medicines including compliance to Good Manufacturing Practices (GMP) and quality standards of drugs given in the respective pharmacopoeia. Proof of safety & effectiveness required for issuing manufacturing license for various categories of ASU medicines is prescribed in Rule 158B of the Drugs & Cosmetics Rules, 1945. Accordingly, the Licensing Authorities/Drugs Controllers appointed by the State Governments are empowered to grant or renew license for manufacturing of ASU medicines and to take necessary action against the defaulters acting in contravention of the legal provisions.

Herbal medicines as such are not defined in the Drugs & Cosmetics Act, 1940 and Rules there under. However, Ayurvedic, Siddha and Unani (ASU) medicines made from herbal/plant materials and other ingredients are regulated in the country through exclusive quality control provisions given in the Drugs & Cosmetics Act 1940 and Rules there under. Instances of fake such medicines have been reported, which are defined in chapter IV A of the Drugs & Cosmetics Act, 1940 as spurious, misbranded and adulterated types along with the penal provisions for the defaulters. Complaints of substandard medicines are forwarded to the respective State Regulatory Authorities for taking action in accordance with the legal provisions.

Reports of testing of ASU drugs received in this regard from some of the states and central laboratory during 2017-18 are as under-
State No. of drug samples taken for testing No. of samples not qualified Action taken in accordance with the provisions of Drugs & Cosmetics Act and Rules. Kerala 570 15 Prosecution action and Departmental action are being taken against the defaultersChhattisgarh 50 03 Action was taken as per recommendation of Screening Committee formed as per Govt. of India.Chandigarh 432 Nil -Delhi 2346 19 08 cases are under process in Court. Gujarat 76 00 ----Himachal Pradesh 487 44 Action has been taken as per Drugs & Cosmetics Act, 1940 and Rules 1945.Odisha 53 Nil ---Karnataka 1056 29 Failed batches of medicine are withdrawn from the Market. Show cause notices issued and manufacturers instructed not to issue the failed batch of medicines. Sale of failed batches of medicines banned.Tamil nadu 1255 39 Show cause notices issued. Telangana 315 Nil Tripura 146 Nil Uttarakhand 138 34 Show cause notices issued. Pudducherry 16 Nil Central Pharmacopoeia Laboratory of Indian Medicine (PLIM) 07 01 Test Reports submitted to Hon'ble Court.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 06 2018 | 6:23 PM IST

Next Story